Panion & Bf Biotech (TPE:1760) Other Current Assets: NT$73 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1760 Panion & Bf Biotech Inc TPE:1760
72 GF Score
Price NT$59.70
GF Value NT$96.06
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Panion & Bf Biotech Other Current Assets?

Panion & Bf Biotech TPE:1760 -1.32% 72 Other Current Assets is NT$73 Mil as of Dec. 2025. GuruFocus rates TPE:1760 with a GF Score™ of 72/100 and a GF Value™ of NT$96.06 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Panion & Bf Biotech's other current assets for the quarter that ended in Dec. 2025 was NT$73 Mil.

Panion & Bf Biotech's quarterly other current assets increased from Jun. 2025 (NT$67 Mil) to Sep. 2025 (NT$86 Mil) but then declined from Sep. 2025 (NT$86 Mil) to Dec. 2025 (NT$73Mil).

Panion & Bf Biotech's annual other current assets increased from Dec. 2023 (NT$52 Mil) to Dec. 2024 (NT$57 Mil) increased from Dec. 2024 (NT$57 Mil) to Dec. 2025 (NT$73 Mil).


Panion & Bf Biotech Other Current Assets Related Terms


Panion & Bf Biotech Other Current Assets Historical Data

* Premium members only.

The historical data trend for Panion & Bf Biotech's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panion & Bf Biotech Other Current Assets Chart

Panion & Bf Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.36 34.06 51.91 57.27 73.00

Panion & Bf Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.27 62.31 66.65 85.58 73.00
TPE:1760
72GF Score
Panion & Bf Biotech Inc TPE:1760
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panion & Bf Biotech Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of NT$73 Mil mean?
Panion & Bf Biotech (TPE:1760) has a Other Current Assets of NT$73 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Panion & Bf Biotech.
Is Panion & Bf Biotech's Other Current Assets too high?
Panion & Bf Biotech's current Other Current Assets is NT$73 Mil. Overall, Panion & Bf Biotech has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Other Current Assets compare to ZTS?
Panion & Bf Biotech's Other Current Assets of NT$73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Panion & Bf Biotech. Panion & Bf Biotech's current Other Current Assets is NT$73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.06, compared to a current price of NT$59.70 — trading 37.9% below its estimated fair value. The current Other Current Assets is NT$73 Mil. Panion & Bf Biotech's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Other Current Assets is NT$73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?

Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued. The current stock price of NT$59.70 is trading 37.9% below its estimated GF Value™ of NT$96.06. GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1760:

  • Other Current Assets: NT$73 Mil
  • GF Value™: NT$96.06 vs. price of NT$59.70 (37.9% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panion & Bf Biotech Business Description

Address No. 3, Park Street, 16th Floor, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
72GF Score

Get the complete analysis for TPE:1760

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.70
Price
NT$96.06
GF Value